We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

95 hedge funds and large institutions have $23.2M invested in Celldex Therapeutics in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.56% less ownership

Funds ownership: 2.53% → 1.97% (-0.56%)

7% less funds holding

Funds holding: 102 → 95 (-7)

15% less call options, than puts

Call options by funds: $11K | Put options by funds: $13K

15% less capital invested

Capital invested by funds: $27.4M → $23.2M (-$4.23M)

32% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 31

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Holders
95
Holders Change
-7
Holders Change %
-6.86%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
21
Reduced
31
Closed
16
Calls
$11K
Puts
$13K
Net Calls
-$2K
Net Calls Change
+$47K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$524K
2
GCP
GSA Capital Partners
United Kingdom
+$294K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$197K
4
Two Sigma Investments
Two Sigma Investments
New York
+$170K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$159K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$689K
2
TCMG
TSP Capital Management Group
New Jersey
-$620K
3
GPP
Great Point Partners
Connecticut
-$405K
4
PP
Paloma Partners
Connecticut
-$323K
5
Deutsche Bank
Deutsche Bank
Germany
-$299K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
51
Virtu Financial
New York
$10K -$1.15K -164 -10%
RJA
52
Raymond James & Associates
Florida
$10K -$21 -3 -0.2%
Creative Planning
53
Creative Planning
Kansas
$10K +$2.86K +409 +40%
LP
54
LMR Partners
United Kingdom
$9K -$181K -25,893 -95%
Principal Financial Group
55
Principal Financial Group
Iowa
$9K +$322 +46 +3%
HF
56
HRT Financial
New York
$8K +$3K +428 +54%
TRCT
57
Tower Research Capital (TRC)
New York
$8K +$8.38K +1,197 New
AG
58
Advisor Group
Arizona
$7K – – –
USAA
59
United Services Automobile Association
Texas
$7K – – –
LTFS
60
Ladenburg Thalmann Financial Services
Florida
$7K +$7.46K +1,066 +3,948%
FWCM
61
Ferguson Wellman Capital Management
Oregon
$7K +$7.51K +1,073 New
Commonwealth Equity Services
62
Commonwealth Equity Services
Massachusetts
$6K +$742 +106 +13%
Koshinski Asset Management
63
Koshinski Asset Management
Illinois
$6K +$6.63K +947 New
BIA
64
Barry Investment Advisors
Massachusetts
$5K – – –
BWP
65
BSW Wealth Partners
Colorado
$5K – – –
Man Group
66
Man Group
United Kingdom
$5K – – –
TAM
67
Tocqueville Asset Management
New York
$5K – – –
SWP
68
Stratos Wealth Partners
Ohio
$5K +$4.67K +667 New
TSS
69
Two Sigma Securities
New York
$5K +$5.64K +806 New
Barclays
70
Barclays
United Kingdom
$3K -$79.2K -11,316 -96%
FDCDDQ
71
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.25K – – –
IP
72
Intellectus Partners
California
$2K – – –
WAM
73
Wealthspire Advisors (Maryland)
Maryland
$2K – – –
Fidelity Investments
74
Fidelity Investments
Massachusetts
$2K +$1.96K +280 New
BNP Paribas Financial Markets
75
BNP Paribas Financial Markets
France
$1.23K – – –
1 2
3
4 5

CLDX Hedge Fund Activity: Q3 2018 in Review

95 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2018, worth a combined $23.2M — down 15% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CLDX and 9 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 21 added.

The largest buyer was Renaissance Technologies, adding an estimated $524K. The largest seller was Goldman Sachs, cutting an estimated $689K.

  • 95 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2018, down from 102 in Q2 2018.
  • Funds reported $23.2M of Celldex Therapeutics stock for Q3 2018, down 15% quarter-over-quarter.
  • 9 funds opened new Celldex Therapeutics positions in Q3 2018 and 16 closed out, a net change of -7 holders.
  • The largest Celldex Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $524K added.
  • The largest Celldex Therapeutics seller in Q3 2018 was Goldman Sachs, an estimated $689K sold.

Based on aggregated 13F filings for Q3 2018.